Talphera (NASDAQ:TLPH – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.14, Zacks reports.
Talphera Price Performance
Talphera stock opened at $0.53 on Wednesday. Talphera has a 12 month low of $0.45 and a 12 month high of $1.27. The stock has a market capitalization of $9.03 million, a PE ratio of -0.77 and a beta of 0.20. The business has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.71.
Analysts Set New Price Targets
A number of research analysts have issued reports on the company. RODMAN&RENSHAW raised Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of Talphera in a research note on Tuesday, January 28th. They issued a “buy” rating and a $4.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Talphera in a research report on Tuesday.
About Talphera
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Read More
- Five stocks we like better than Talphera
- Most active stocks: Dollar volume vs share volume
- Will 2025 Be the Year the Energy Sector Finally Breaks Out?
- When to Sell a Stock for Profit or Loss
- NextEra Energy Stock Sees Spike in Bullish Call Activity
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Top 3 Stocks Mega Investors Are Buying Now
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
